or pharmaceutical acceptable salts thereof wherein:

G is

 R_1 is

- a) H,
- b) NH₂,
- c) NH-C₁₋₄ alkyl,
- d) C₁₄ alkyl,
- e) -OC₁₋₄ alkyl,
- f) $-S C_{14}$ alkyl,
- g) C₁₄ alkyl substituted with 1-3 F, 1-2 Cl, CN or -COOC₁₄ alkyl,
- h) C₃₋₆ cycloalkyl,
- i) N(C₁₋₄ alkyl)₂ or
- j) N(CH₂)_{2.5};

A is

 a 5-membered heteroaromatic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the 5-membered heteroaromatic moiety is bonded via a carbon atom,

wherein the 5-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring,

wherein the heteroaromatic moiety is optionally substituted with one to three R_{48} ,

e) a 6-membered heteroaromatic moiety having at least one nitrogen atom,

wherein the heteroaromatic moiety is bonded via a carbon atom,

wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring,

wherein the heteroaromatic moiety is optionally substituted with one to three $R_{55}, \label{eq:R55}$

f) a β -carbolin-3-yl, or indolizingl bonded via the 6-membered ring, optionally substituted with one to three R_{55} , --

wherein R₂ is

- a) H,
- b) F,
- c) Cl,
- d) Br,
- e) C₁₋₃ alkyl,
- f) NO₂, or
- g) R_2 and R_3 taken together are -O-(CH_2)_h-O-;

R₃ is

- a) $-S(=O)_i R_4$
- b) $-S(=O)_2-N=S(O)_iR_5R_6$,
- c) $-SC(=O)R_7$,
- d) $-C(=O)R_8$
- e) $-C(=O)R_9$,
- f) $-C(=O)NR_{10}R_{11}$,
- g) $-C(=NR_{12})R_8$,
- h) $-C(R_8)(R_{11})-OR_{13}$,
- i) $-C(R_9)(R_{11})-OR_{13}$,
- j) $-C(R_8)(R_{11})-OC(=O)R_{13}$,
- k) $-C(R_9)(R_{11})-OC(=O)R_{13}$,
- 1) $-NR_{10}R_{11}$,
- m) $-N(R_{10})-C(=O)R_7$,
- n) $-N(R_{10})-S(=O)_iR_7$,
- o) $-C(OR_{14})(OR_{15})R_8$,
- p) $-C(R_8)(R_{16})-NR_{10}R_{11}$, or
- q) C_{1.8} alkyl substituted with one or more =O other than at alpha position, -S(=O)_iR₁₇, -NR₁₀R₁₁, C_{2.5} alkenyl, or C_{2.5} alkynyl;

R4 is

a) C_{14} alkyl optionally substituted with one or more halos, OH, CN, $NR_{10}R_{11}$, or $-CO_2R_{13}$,

- b) C₂₄ alkenyl,
- c) $-NR_{16}R_{18}$,
- d) $-N_3$,
- e) $-NHC(=O)R_{7}$
- f) $-NR_{20}C(=O)R_{7}$,
- g) $-N(R_{19})_2$,
- h) $-NR_{16}R_{19}$, or
- i) $-NR_{19}R_{20}$,

R₅ and R₆ at each occurrence are the same or different and are

- a) C₁₋₂ alkyl, or
- b) R_s and R_s taken together are -(CH₂)_k-;

 R_7 is C_{14} alkyl optionally substituted with one or more halos;

R₈ is

- a) H, or
- b) C₁₋₈ alkyl optionally substituted with one or more halos, or C₃₋₈ cycloalkyl;

R₉ is C₁₋₄ alkyl substituted with one or more

- a) $-S(=0)R_{17}$,
- b) -OR₁₃,
- c) $-OC(=O)R_{13}$,
- d) $-NR_{10}R_{11}$, or
- e) C_{1.5} alkenyl optionally substituted with CHO;

 R_{10} and R_{11} at each occurrence are the same or different and are

- a) H,
- b) C₁₄ alkyl, or
- c) C₃₋₈ cycloalkyl;

R₁₂ is

- a) $-NR_{10}R_{11}$,
- b) -OR₁₀; or
- c) $-NHC(=O)R_{10}$;



R₁₃ is

- a) H, or
- b) C₁₄ alkyl;

 $\ensuremath{R_{\text{14}}}$ and $\ensuremath{R_{\text{15}}}$ at each occurrence are the same or different and are

- a) C₁₄ alkyl, or
- b) R_{14} and R_{15} taken together are -(CH)₁-;

 R_{16} is

- a) H,
- b) C₁₄ alkyl, or
- c) C₃₋₈ cycloalkyl;

R₁₇ is

- a) C₁₄ alkyl, or
- b) C₃₋₈ cycloalkyl;

R₁₈ is

- a) H,
- b) C₁₋₄ alkyl,
- c) C₂₄ alkenyl,
- d) C₃₋₄ cycloalkyl,
- e) -OR₁₃ or
- f) $-NR_{21}R_{22}$;

R₁₉ is

- a) Cl,
- b) Br, or
- c) I;

R₂₀ is a physiologically acceptable cation;

 R_{21} and R_{22} at each occurrence are the same or different and are

- a) H,
- b) C₁₋₄ alkyl, or
- c) -NR₂₁R₂₂ taken together are -(CH₂)_m-;

wherein R_{23} and R_{24} at each occurrence are the same or different and are

- a) H,
- b) F,



- c) Cl,
- d) C₁₋₂ alkyl,
- CN e)
- OH, f)
- g) C₁₋₂ alkoxy,
- h) nitro, or
- i) amino;

Q is


b)



c)



d)



e)



h)



j)



k)

l)

m) a diazinyl group optionally substituted with X and Y,

n) a triazinyl group optionally substituted with X and Y,

o) a quinolinyl group optionally substituted with X and Y,

p) a quinoxalinyl group optionally substituted with X and Y,

q) a naphthyridinyl group optionally substituted with X and Y,

r)

$$A^{1} \xrightarrow{A^{2}} (CH_{2})_{n}$$

$$Z^{1} \xrightarrow{N} N$$

)

s)

t)

u)

v)

w)


x)

y)

z)

aa)

bb)




or,

Q and R24 taken together are

wherein Z1 is





d)
$$-CH_2CH_2CH_2$$
-;

wherein Z2 is

a)
$$-O_2S$$
-,

c)
$$-N(R^{107})$$
-,

wherein Z³ is

a)
$$-O_2S$$
-,

wherein A1 is

wherein A2 is

- a) H-,
- b) HO-,
- c) CH₃-,
- d) CH₃O-,
- e) $R^{102}O-CH_2-C(O)-NH-$
- f) R¹⁰³O-C(O)-NH-,
- g) (C_1-C_2) alkyl-O-C(O)-,
- h) HO-CH₂-,
- i) CH₃O-NH-,
- j) (C₁-C₃)alkyl-O₂C-
- k) $CH_3-C(O)$ -,
- 1) CH₃-C(O)-CH₂-,

m)



, or

n)

A¹ and A² taken together are:

a)

b)

o =

, or

wherein R102 is

- a) H-,
- b) CH₃-,
- c) phenyl-CH₂-, or
- d) CH₃C(O)-;

wherein R¹⁰³ is

- a) (C_1-C_3) alkyl-, or
- b) phenyl-;

wherein R104 is

- a) H-, or
- b) HO-;

wherein R105 is

- a) H-,
- b) (C_1-C_3) alkyl-,
- c) $CH_2 = CH-CH_2$, or
- d) $CH_3-O-(CH_2)_2-;$

wherein R106 is

- a) CH_3 -C(O)-,
- b) H-C(O)-,
- c) Cl₂CH-C(O)-,
- d) $HOCH_2$ -C(O)-,
- e) CH_3SO_2 -,

g) $F_2CHC(O)$ -,

- i) H₃C-C(O)-O-CH₂-C(O)-,
- j) H-C(O)-O-CH₂-C(O)-,

- l) HC=C-CH₂O-CH₂-C(O)-, or
- m) phenyl-CH₂-O-CH₂-C(O)-;

wherein R107 is

- a) $R^{102}O-C(R^{110})(R^{111})-C(O)-$,
- b) $R^{103}O-C(O)$ -,
- c) R^{108} -C(O)-,

- f) H₃C-C(O)-(CH₂)₂-C(O)-,
- g) R^{109} - SO_{2} -,

h)

i) HO-CH₂-C(O)-,

- j) R¹¹⁶-(CH₂)₂-,
- k) R¹¹³-C(O)-O-CH₂-C(O)-,
- l) (CH₃)₂N-CH₂-C(O)-NH-,
- m) $NC-CH_2$ -,
- n) F_2 -CH-CH₂-, or
- o) R¹⁶⁰R¹⁶¹NSO₂

wherein R108 is

- a) H-,
- b) (C_1-C_4) alkyl,
- c) aryl $-(CH_2)_p$,
- d) ClH₂C-,
- e) Cl₂HC-,
- f) FH₂C-,
- g) F_2HC_{-}
- h) (C₃-C₆)cycloalkyl, or
- i) CNCH₂-.

wherein R109 is

- a) alkyl C_1 - C_4 ,
- b) -CH₂Cl
- c) -CH₂CH=CH₂,
- d) aryl, or
- e) -CH₂CN;

wherein R110 and R111 are independently

- a) H-,
- b) CH_3 -; or

wherein R112 is

- a) H-,
- b) CH₃O-CH₂O-CH₂-, or
- c) HOCH₂-;



wherein R113 is

- a) CH_{3} -,
- b) HOCH₂-,
- c) (CH₃)₂N-phenyl, or
- d) (CH₃), N-CH₂-;

wherein R114 is

- a) HO-,
- b) CH₃O-,
- c) H_2N_- ,
- d) CH₁O-C(O)-O-,
- e) CH_3 -C(O)-O- CH_2 -C(O)-O-,
- f) phenyl-CH₂-O-CH₂-C(O)-O-,
- g) $HO-(CH_2)_2-O-$,
- h) CH₃O-CH₂-O-(CH₂)₂-O-, or
- i) CH₃O-CH₂-O-; wherein R¹¹³ is
- a) CH_{3} ,
- b) $HOCH_2$ -,
- c) (CH₃)₂N-phenyl, or
- d) $(CH_3)_2N-CH_2-;$

wherein R115 is

- a) H-, or
- b) Cl-;

wherein R116 is

- a) HO-
- b) CH₃O-, or
- c) F;

wherein R^{150} and R^{151} are each H or alkyl C_1 - C_4 or R^{150} and R^{151} taken together with the nitrogen atom to which each is attached form a monocyclic heterocyclic ring having from 3 to 6 carbon atoms;

B is an unsaturated 4-atom linker having one nitrogen and three carbons; M is



- a) H,
- b) C₁₋₈ alkyl,
- c) C₃₋₈ cycloalkyl,
- d) $-(CH_2)_mOR_{13}$, or
- e) -(CH₂)_h-NR₂₁R₂₂;

Z is

- a) O,
- b) S, or
- c) NM;

W is

- a) CH,
- b) N, or
- c) S or O when Z is NM;

Y is

- a) H,
- b) F, -,
- c) Cl,
- d) Br,
- e) C₁₋₃ alkyl, or
- f) NO₂;

X is

- a) H,
- b) -CN,
- c) OR₂₇,
- d) halo,
- e) NO₂,
- f) tetrazoyl,
- g) -SH,
- h) $-S(=O)_iR_4$,
- i) $-S(=O)_2-N=S(O)_jR_5R_6$,



- j) -SC(=O) R_7 ,
- k) $-C(=O)R_{25}$
- 1) $-C(=O)NR_{27}R_{28}$,
- m) $-C(=NR_{29})R_{25}$,
- n) $-C(R_{25})(R_{28})-OR_{13}$
- o) $-C(R_{25})(R_{28})-OC(=O)R_{13}$
- p) $-C(R_{28})(OR_{13})-(CH_2)_b-NR_{27}R_{28}$
- q) -NR₂₇R₂₈,
- r) $-N(R_{27})C(=O)R_{7}$
- s) $-N(R_{27})-S(=O)_{i}R_{7}$
- t) $-C(OR_{14})(OR_{15})R_{28}$
- u) $-C(R_{25})(R_{16})-NR_{27}R_{26}$, or
- v) $C_{1.8}$ alkyl substituted with one or more halos, OH, =O other than at alpha position, -S(=O)_iR₁₇, -NR₂₇R₂₈, C_{2.5} alkenyl, C_{2.5} alkynyl, or $C_{3.8}$ cycloalkyl;

 R_4 , R_5 , R_6 , R_7 , R_{13} , R_{14} , R_{15} , R_{16} , and R_{17} are the same as defined above; R_{25} is

- a) H,
- b) $C_{1.8}$ alkyl optionally substituted with one or more halos, $C_{3.8}$ cycloalkyl, $C_{1.4}$ alkyl substituted with one or more of -S(=O)_iR₁₇, -OR... or OC(=O)R₁₃, NR₂₇R₂₈, or
- c) C_{2.5} alkenyl optionally substituted with CHO, or CO₂R₁₅;

R₂₆ is

- a) R₂₈, or
- b) $NR_{27}N_{28}$;

 R_{27} and R_{28} at each occurrence are the same or different and are

- a) H,
- b) C_{1-8} alkyl,
- c) C₃₋₈ cycloalkyl,
- d) $-(CH_2)_mOR_{13}$,



- e) $-(CH_2)_h-NR_{21}R_{22}$, or
- f) R_{27} and R_{28} taken together are $-(CH_2)_2O(CH_2)_2$ -, $-(CH_2)_hCH(COR_7)$ -, or $-(CH_2)_2N(CH_2)_2(R_7)$;

R_{29} is

- a) $-NR_{27}R_{28}$,
- b) -OR₂₇ or
- c) $-NHC(=O)R_{28}$;

wherein R₃₀ is

- a) H,
- b) C_{1.8} alkyl optionally substituted with one or more halos, or
- c) $C_{1.8}$ alkyl optionally substituted with one or more OH, or $C_{1.6}$ alkoxy;

wherein E is

- a) NR₃₉,
- b) $-S(=O)_i$, or
- c) O;

R_{38} is

- a) H,
- b) C₁₋₆ alkyl,
- c) $-(CH_2)_q$ -aryl, or
- d) halo;

R₃₉ is

- a) H,
- b) C₁₋₆ alkyl optionally substituted with one or more OH, halo, or -CN,
- c) -(CH₂)_q-aryl,
- d) $-CO_2R_{40}$
- e) -COR₄₁,
- f) $-C(=O)-(CH_2)_q-C(=O)R_{40}$,
- g) $-S(=O)_2-C_{1-6}$ alkyl,
- h) $-S(=O)_2-(CH_2)_q$ -aryl, or
- i) -(C=O);-Het;



R₄₀ is

- a) H,
- b) C₁₆ alkyl optionally substituted with one or more OH, halo, or -CN,
- c) -(CH₂)_q-aryl, or
- d) $-(CH_2)_q OR_{42}$;

R41 is

- a) C₁₋₆ alkyl optionally substituted with one or more OH, halo, or -CN,
- b) -(CH₂),-aryl, or
- c) -(CH₂)_q-OR₄₂;

R_{42} is

- a) H,
- b) C₁₋₆ alkyl,
- c) -(CH₂)_q-aryl, or
- d) $-C(=O)-C_{1-6}$ alkyl;

aryl is

- a) phenyl,
- b) pyridyl, or
- c) napthyl; a to c optionally substituted with one or more halo, -CN, OH, SH, C₁₆ alkyl, C₁₆ alkoxy, or C₁₆ alkylthio;

wherein R43 is

- a) H,
- b) C₁₋₂ alkyl,
- c) F, or
- d) OH;

R_{44} is

- a) H,
- b) CF₃,
- c) C₁₃ alkyl optionally substituted with one or more halo,
- d) phenyl optionally substituted with one or more halo,



e) R₄₄ and R₄₅ taken together are a 5-, 6-, or 7-membered ring of the formula,

or

f) R_{44} and R_{45} taken together are -(CH₂)_k-, when R_{46} is an electron-withdrawing group;

 $R_{45} \ \text{and} \ R_{46} \ \text{at each occurrence}$ are the same or different and are

- a) an electron-withdrawing group,
- b) H,
- c) CF₃,
- d) C_{1.3} alkyl optionally substituted with one halo,
- e) phenyl, provided at least one of R_{45} or R_{46} is an electron-withdrawing group, or
- f) R_{45} and R_{46} taken together are a 5-, 6-, 7-membered ring of the formula

U is

- a) CH₂,
- b) O,
- c) S, or
- d) NR₄₇;

R₄₇ is

- a) H, or
- b) C_{1.5} alkyl;

wherein R48 is

- a) carboxyl,
- b) halo,
- c) -CN,
- d) mercapto,
- e) formyl,
- f) CF_3 ,
- g) -NO₂,
- h) C_{1.6} alkoxy,
- i) C₁₋₆ alkoxycarbonyl,
- j) C_{1.5} alkythio,
- k) C₁₋₆ acyl,
- . 1) $-NR_{49} R_{50}$,
- m) $C_{1.5}$ alkyl optionally substituted with OH, $C_{1.5}$ alkoxy, $C_{1.5}$ acyl, or $-NR_{49}R_{50}$,
- n) C₂₋₈ alkenylphenyl optionally substituted with one or two R₅₁,
- o) phenyl optionally substituted with one or two R_{51} ,
- p) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two R_{51} , or

 R_{49} and R_{50} at each occurrence are the same or different and are

- a) H,
- b) C₁₄ alkyl,
- c) C₅₋₆ cycloalkyl, or

d) R₄₉ and R₅₀ taken together with the nitrogen atom is a 5-, 6membered saturated heterocyclic moiety which optionally has a
further hetero atom selected from the group consisting of S, N, and O,
and can in turn be optionally substituted with, including on the
further nitrogen atom, C₁₋₃ alkyl, or C₁₋₃ acyl;

$R_{\delta 1}$ is

- a) carboxyl,
- b) halo,
- c) -CN,
- d) mercapto,
- e) formyl,
- f) CF_3 ,
- g) -NO₂,
- h) C₁₋₆ alkoxy,
- i) C₁₋₆ alkoxycarbonyl,
- j) C₁₋₆ alkythio,
- k) C₁₋₆ acyl,
- l) C_{1-5} alkyl optionally substituted with OH, C_{1-5} alkoxy, C_{1-5} acyl, or $-NR_{49}R_{50}$,
- m) phenyl,
- n) $-C(=O)NR_{52}R_{53}$
- o) $-NR_{49}R_{50}$,
- p) $-N(R_{52})(-SO_2R_{54})$,
- q) $-SO_2-NR_{52}R_{53}$, or
- r) $-S(=O)_i R_{sa}$;

 $R_{\rm 52}$ and $R_{\rm 53}$ at each occurrence are the same or different and are

- a) H,
- b) C₁₋₆ alkyl, or
- c) phenyl;




R₅₄ is

- a) C₁₄ alkyl, or
- b) phenyl optionally substituted with C_{i-1} alkyl;

wherein Rss is

- a) carboxyl,
- b) halo,
- c) -CN,
- d) mercapto,
- e) formyl,
- f) CF₃,
- g) -NO₂,
- h) C₁₋₆ alkoxy,
- i) C₁₋₆ alkoxycarbonyl,
- j) C₁₋₆ alkythio
- k) C_{1-6} acyl,
- $1) -NR_{56} R_{57},$
- m) $C_{1.6}$ alkyl optionally substituted with OH, $C_{1.5}$ alkoxy, $C_{1.5}$ acyl, or $-NR_{56}R_{57}$,
- n) $C_{2.8}$ alkenylphenyl optionally substituted with one or two R_{58} ,
- o) phenyl optionally substituted with one or two R_{58} ,
- p) a 5- or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two R_{58} , or



 R_{s6} and R_{s7} at each occurrence are the same or different and are

- a) H,
- b) formyl,



- c) C₁₄ alkyl,
- d) C₁₋₄ acyl,
- e) phenyl,
- f) C₃₋₆ cycloalkyl, or
- g) R₅₆ and R₅₇ taken together with the nitrogen atom is a 5-, 6membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, phenyl, pyrimidyl, C₁₋₃ alkyl, or C₁₋₃ acyl;

 R_{58} is

- a) carboxyl,
- b) halo,
- c) -CN,
- d) mercapto,
- e) formyl,
- f) CF_{s} ,
- g) -NO₂,
- h) C₁₋₆ alkoxy,
- i) C₁₋₆ alkoxycarbonyl,
- j) C₁₋₆ alkythio,
- k) C₁₋₆ acyl,
- l) phenyi,
- m) C_{1-6} alkyl optionally substituted with OH, azido, C_{1-5} alkoxy, C_{1-5} acyl, $-NR_{55}R_{56}$, $-SR_{57}$, $-O-SO_2R_{58}$, or

- n) $-C(=O)NR_{59}R_{60}$,
- o) $-NR_{66}R_{57}$,
- p) $-N(R_{59})(-SO_2R_{54})$,



- q) $-SO_2-NR_{59}R_{60}$,
- r) -S(=O)_iR₅₄,
- s) $-CH=N-R_{61}$, or
- t) $-CH(OH)-SO_3R_{64}$;

 $R_{\rm 54}$ is the same as defined above;

 $R_{59} \ and \ R_{60}$ at each occurrence are the same or different and are

- a) H,
- b) C_{1.6} alkyl,
- c) phenyl, or
- d) tolyl;

R₆₁ is

- a) OH,
- b) benzyloxy,
- c) $-NH-C(=O)-NH_2$,
- d) $-NH-C(=S)-NH_2$, or
- e) -NH-C(=NH)-N $R_{62}R_{63}$;

 R_{62} and R_{63} at each occurrence are the same or different and are

- a) H, or
- b) C₁₄ alkyl optionally substituted with phenyl or pyridyl;

R₆₄ is

- a) H, or
- b) a sodium ion;

 R_{65} and R_{66} at each occurrence are the same or different and are

- a) H,
- b) formyl,
- c) C₁₄ alkyl,
- d) C₁₋₄ acyl,
- e) phenyl,
- f) C_{3.6} cycloalkyl,



- g) R₆₅ and R₆₆ taken together are a 5-, 6-membered saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with, including on the nitrogen atom, phenyl, pyrimidyl, C₁₋₃ alkyl, or C₁₋₃ acyl,
- h) $-P(O)(OR_{70})(OR_{71})$, or
- i) $-SO_2-R_{72}$;

R₆₇ is

R₆₈ is C₁₋₃ alkyl;

 R_{69} is

- a) C₁₋₆ alkoxycarbonyl, or
- b) carboxyl;

 R_{70} and R_{71} at each occurrence are the same or different and are

- a) H, or
- b) C_{1.3} alkyl;

R_{72} is

- a) methyl,
- b) phenyl, or
- c) tolyl;

wherein K is

- a) O, or
- b) S;

 R_{73} , R_{74} , R_{75} , R_{76} , and R_{77} at each occurrence are the same or different and are

- a) H,
- b) carboxyl,
- c) halo,
- d) -CN.
- e) mercapto,
- f) formyl,
- g) CF₃,
- h) -NO₂,
- i) C₁₋₆ alkoxy,
- j) C₁₋₆ alkoxycarbonyl,
- k) C_{1.6} alkythio,
- $C_{1.6}$ acyl,
- m) $-NR_{78}R_{79}$,
- n) C_{1.6} alkyl optionally substituted with OH, C_{1.5} alkoxy, C_{1.5} acyl,
 -NR₇₈R₇₉, -N(phenyl)(CH₂-CH₂-OH), -O-CH(CH₃)(OCH₂CH₃), or
 -O-phenyl-[para-NHC(=O)CH₃],
- o) $C_{2.8}$ alkenylphenyl optionally substituted with R_{51} ,
- p) phenyl optionally substituted with R_{51} , or
- q) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with R₅₁;

R₅₁ is the same as defined above;



R₇₈ and R₇₉ at each occurrence are the same or different and are

- a) H,
- b) C_{1-1} alkyl,
- c) phenyl, or
- d) R₇₈ and R₇₉ taken together with the nitrogen atom is a 5-, 6membered saturated heterocyclic moiety which optionally has a
 further hetero atom selected from the group consisting of S, N, and O,
 and can in turn be optionally substituted with, including on the
 further nitrogen atom, C₁₋₃ alkyl, or C₁₋₃ acyl;

wherein T is

- a) O,
- b) S, or
- c) SO₂;

 R_{75} , R_{76} , and R_{77} are the same as defined above;

R₈₀ is

- a) H,
- b) formyl,
- c) carboxyl,
- d) C₁₋₆ alkoxycarbonyl,
- e) C_{1.8} alkyl,
- f) $C_{2.6}$ alkenyl,
 wherein the substituents (e) and (f) can be optionally substituted with
 OH, halo, $C_{1.6}$ alkoxy, $C_{1.6}$ acyl, $C_{1.6}$ alkylthio or $C_{1.6}$ alkoxycarbonyl, or phenyl optionally substituted with halo,
- g) an aromatic moiety having 6 to 10 carbon atoms optionally substituted with carboxyl, halo, -CN, formyl, CF₃, -NO₂, C_{1.6} alkyl, C_{1.6} alkoxy, C_{1.6} acyl, C_{1.6} alkylthio, or C_{1.6} alkoxycarbonyl;
- h) $-NR_{81}R_{82}$
- i) $-OR_{90}$
- j) $-S(=O)_i-R_o$
- k) $-SO_2-N(R_{92})(R_{93})$, or
- a radical of the following formulas:



 $R_{\rm si}$ and $R_{\rm s2}$ at each occurrence are the same or different and are

- a) H,
- b) C₃₋₆ cycloalkyl,
- c) phenyl,
- d) C₁₋₆ acyl,
- e) C_{1.8} alkyl optionally substituted with OH, C_{1.6} alkoxy which can be substituted with OH, a 5-, or 6-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, phenyl optionally substituted with OH, CF₃, halo, -NO₂, C_{1.4} alkoxy, -NR₂₃R₃₄, or

$$g)$$
 $\sqrt{N-(CH_2)_t}-$

V is

- a) O,
- b) CH₂, or
- c) NR₈₇;

 $R_{\rm 83}$ and $R_{\rm 84}$ at each occurrence are the same or different and are

- a) H, or
- b) C₁₄ alkyl;

R₈₅ is

- a) OH,
- b) C₁₄ alkoxy, or
- c) -NR₈₈ R₈₉;

R₈₆ is

- a) H, or
- b) C_{1.7} alkyl optionally substituted with indolyl, OH, mercaptyl, imidazoly, methylthio, amino, phenyl optionally substituted with OH, -C(=O)-NH₂, -CO₂H, or -C(=NH)-NH₂;

 R_{87} is

- a) H,
- b) phenyl, or
- c) C_{1.6} alkyl optionally substituted by OH;

 R_{88} and R_{89} at each occurrence are the same or different and are

- a) H,
- b) C_{1.5} alkyl
- c) C_{3.6} cycloalky, or
- d) phenyl;

 R_{90} is

a) C_{1.6} alkyl optionally substituted with C_{1.6} alkoxy or C_{1.6} hydroxy, C_{3.6} cycloalkyl, a 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three nitrogen atoms, which can in turn be substituted with one or two -NO₂, CF₃, halo, -CN, OH, C_{1.5} alkyl, C_{1.5} alkoxy, or C_{1.5} acyl;

- c) phenyl, or
- d) pyridyl;



R₉₁ is

- a) C_{1-16} alkyl,
- b) C₂₋₁₆ alkenyl,
 wherein the substituents (a) and (b) can be optionally substituted with
 C₁₋₆ alkoxycarbonyl, or a 5-, 6-, 7-membered aromatic heterocyclic
 moiety having one to three atoms selected from the group consisting of
 S, N, and O,
- c) an aromatic moiety having 6 to 10 carbon atoms, or
- a 5-, 6-, 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (c) and (d) can be optionally substituted with carboxyl, halo, -CN, formyl, CF₃, -NO₂, C_{1.6} alkyl, C_{1.6} alkoxy, C_{1.6} acyl, C_{1.6} alkylthio, or C_{1.6} alkoxycarbonyl;

 $R_{\rm 92}$ and $R_{\rm 93}$ at each occurrence are the same or different and are

- a) H,
- b) phenyl,
- c) C₁₋₆ alkyl, or
- d) benzyl;

 R_{94} and R_{95} at each occurrence are the same or different and are

- a) H.
- b) OH,
- c) C₁₆ alkyl optionally substituted with -NR₈₃ R₈₄, or
- d) R_{s4} and R_{s5} taken together are =0;

R_{96} is

- a) an aromatic moiety having 6 to 10 carbon atoms,
- b) a 5-, or 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (a) and (b) which can in turn be substituted with one or three -NO₂, CF₃, halo, -CN, OH, phenyl, C₁₋₅ alkyl, C₁₋₅ alkoxy, or C₁₋₅ acyl,



- c) morpholinyl,
- d) OH,
- e) C₁₋₆ alkoxy,
- f) $-NR_{83}R_{84}$,
- g) $-C(=0)-R_{97}$, or
- h) 0

R₉₇ is

- a) morpholinyl,
- b) OH, or
- c) C₁₋₆ alkoxy;

h is 1, 2, or 3;

i is 0, 1, or 2;

j is 0 or 1;

k is 3, 4, or 5;

1 is 2 or 3;

m is 4 or 5;

n is 0, 1, 2, 3, 4, or 5;

p is 0, 1, 2, 3, 4, or 5; with the proviso that n and p together are 1, 2, 3, 4, or 5;

q is 1, 2, 3, or 4;

r is 2, 3, or 4;

t is 0, 1, 2, 3, 4, 5, or 6;

u is 1 or 2;

w is 0, 1, 2, or 3.



7. (Twice Amended) A method of treating osteoporosis or bone resorption in a vertebrate mammal in need thereof comprising the administering to the vertebrate mammal an effective amount of a compound of formula

wherein Z_2 is $-O_2S_-$, $-O_-$, $-N(R^{107})_-$, $-OS_-$, or $-S_-$; w is 0, 1, 2, or 3;

 R^{23} and R^{24} are the same or different and can be H or F; and

 R^1 is H, NH₂, NHalkylC₁-C₄; N(alkylC₁-C₄)₂; -NClt22s



alkylC₁-C₄; OalkylC₁-C₄; SalkylC₁-C₄; alkylC₁-C₄ substituted with 1-3F, 1-2Cl, CN, or -COOalkylC₁-C₄, or cycloalkylC₃-C₆, wherein in each occurrence of the alkyl group may be straight or branched; and R¹⁰⁷ is

- a) $R^{102}O-C(R^{110})(R^{111})-C(O)-$,
- b) $R^{103}O-C(O)-$,
- c) R^{108} -C(O)-,
- d) R^{109} -SO₂-,
- e) NC-CH₂-,
- f) FCHCH₂-, or
- g) $R^{150}R^{151}NSO_2$;



wherein R¹⁰² is H, CH₃-, phenyl-CH₂-, or CH₃C(O); each of R¹¹⁰ and R¹¹¹ is selected from H or CH₃; R¹⁰³ is alkylC₁-C₃ or phenyl; R¹⁰⁸ is H, alkylC₁-C₄, aryl(CH₂)_{0.5}, CNCH₂-, ClCH₂-, Cl₂HC-, FH₂C-, F₂HC-, or cycloalkylC₃-C₆; R¹⁵⁰ and R¹⁵¹ are the same or different and are selected from H, alkylC₁-C₄, or R¹⁵⁰ and R¹⁵¹ taken together with the nitrogen to which each is attached forms a monocyclic heterocyclic ring having from 3 to 6 carbon atoms.